RNA vaccine
An RNA vaccine is a vaccine whose active genetic component is RNA encoding an antigen.
An RNA vaccine is a vaccine whose active genetic component is RNA encoding an antigen. After delivery into cells—often using a lipid nanoparticle (LNP)—the RNA directs temporary production of the encoded antigen, allowing the immune system to develop humoral and cellular responses. Depending on the antigen and formulation, these responses may include antigen-specific immunoglobulin G, cytotoxic T cells, and broader T cell mediated immunity. Innate immune pathways, including interferon signaling, NF-κB, STAT6, and inflammatory cytokines such as tumor necrosis factor-α, Interleukin-6 (IL-6), interleukin-1β, and interleukin-17A, can also influence the response to vaccination.
RNA vaccines have been investigated for infectious diseases including SARS-CoV-2, respiratory syncytial virus, and chikungunya virus, as well as for therapeutic applications such as pulmonary cancer immunotherapy. The technology includes different RNA chemistries, including unmodified RNA and N1-methylpseudouridine-modified RNA, and can be paired with antigen-engineering strategies designed to broaden immune recognition. Recent work also examines vaccine responses in specific populations, including dialysis patients, and public attitudes toward the use of mRNA vaccination in humans and livestock.
Where the papers sit
17 papers from the last 6 months study RNA vaccine directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 4 observational · 11 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
COVID-19 Vaccine Responses
COVID-19 vaccination research is moving toward broader protection and more tailored use in vulnerable populations. Dialysis and kidney transplant recipients remain central because immunogenicity is reduced or variable. Divergent RBD pairing, nitric oxide-assisted lipid nanoparticles and coadministration with RSV vaccine seek to strengthen or broaden responses. Safety, toxicology, public acceptance and health-related quality of life remain parallel clinical concerns.
8 papers · 47.1%
-
Preclinical mRNA Vaccine Design
Preclinical mRNA vaccine work is advancing antigen stabilization, lipid nanoparticle delivery and tissue-specific immune programming. Studies pursue protective antibody and T-cell responses across RSV, H5N1, chikungunya and fish viruses, while pulmonary delivery is being adapted for cancer immunotherapy. Innate sensing recurs through interferon, RIG-I, NF-κB and STAT6 pathways, linking reactogenicity to efficacy. The common goal is stronger, broader immunity with fewer delivery and inflammation barriers.
7 papers · 41.2%
-
Computational RNA Vaccine Design
Computational vaccine design is being used to nominate RNA immunogens against Trypanosoma brucei and Marburg virus. Reverse vaccinology and immunoinformatics prioritize antigenic regions and predicted immune stimulation before experimental testing. Toll-like receptor interactions, including TLR2, recur as mechanistic targets alongside structural and molecular-dynamics analyses. The work remains at the candidate-design stage, with protective efficacy still requiring laboratory validation.
2 papers · 11.8%
Intratracheal mRNA vaccination is presented as a macrophage-reprogramming treatment for established pulmonary cancer
The pulmonary cancer model studied by the intratracheal-delivery paper treats the mRNA vaccine not merely as a vehicle for eliciting systemic antiviral or antitumor immunity, but as a local intervention that selectively reprograms alveolar macrophages. Intratracheal delivery produced only a modest increase in total pulmonary protein expression over intranasal delivery yet greatly increased functional transfection in alveolar macrophages; their depletion abolished antitumor protection. This assigns the RNA vaccine a distinct therapeutic role as a route-dependent immune-cell-targeting treatment for lung tumors 42579432Aug.
Papers
The 17 papers from the last 6 months that study RNA vaccine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
COVID-19 Vaccine Responses (8)
- Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients. PloS one · 4 Nov 2026 PMID 42981357
- Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the Post-COVID Era". Vaccine · 1 Oct 2026 PMID 42822179
- Associations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore. Journal of infection and public health · 16 Sept 2026 PMID 42748761
- Nitric oxide-assisted lipid nanoparticles amplify mRNA vaccine responses. Journal of controlled release : official journal of the Controlled Release Society · 31 Aug 2026 PMID 42674289
- Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
- Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey. Vaccine · 7 Jul 2026 PMID 42413319
- Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study. Vaccine · 20 Jun 2026 PMID 42322683
- Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 4 Jun 2026 PMID 42240564
Preclinical mRNA Vaccine Design (7)
- Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA vaccine in mice. Vaccine · 2 Oct 2026 PMID 42826690
- Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines. Science translational medicine · 26 Aug 2026 PMID 42647597
- Intratracheal Delivery of mRNA Lipid Nanoparticles Reprograms Alveolar Macrophages for Pulmonary Cancer Immunotherapy. ACS nano · 11 Aug 2026 PMID 42579432
- Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses. Cell reports. Medicine · 3 Aug 2026 PMID 42546698
- An LNP-encapsulated mRNA vaccine targeting the major capsid protein of largemouth bass virus confers protective immunity and reduces RIG-I pathway activation in Micropterus salmoides. Fish & shellfish immunology · 30 Jun 2026 PMID 42379032
- Spatiotemporal atlas of pro-inflammatory NF-κB and anti-inflammatory STAT6 signaling using reporter mice during mRNA vaccination. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Jun 2026 PMID 42231579
- Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines. Biochemical and biophysical research communications · 22 May 2026 PMID 42172905
Computational RNA Vaccine Design (2)
- Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis. PloS one · 23 Oct 2026 PMID 42912726
- Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei. Acta parasitologica · 7 Sept 2026 PMID 42704553
By study type
Clinical trials (1)
- Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 4 Jun 2026 PMID 42240564
Observational studies and case reports (4)
- Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients. PloS one · 4 Nov 2026 PMID 42981357
- Associations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore. Journal of infection and public health · 16 Sept 2026 PMID 42748761
- Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey. Vaccine · 7 Jul 2026 PMID 42413319
- Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study. Vaccine · 20 Jun 2026 PMID 42322683
Preclinical: animal, cell and lab studies (11)
- Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis. PloS one · 23 Oct 2026 PMID 42912726
- Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA vaccine in mice. Vaccine · 2 Oct 2026 PMID 42826690
- Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the Post-COVID Era". Vaccine · 1 Oct 2026 PMID 42822179
- Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei. Acta parasitologica · 7 Sept 2026 PMID 42704553
- Nitric oxide-assisted lipid nanoparticles amplify mRNA vaccine responses. Journal of controlled release : official journal of the Controlled Release Society · 31 Aug 2026 PMID 42674289
- Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines. Science translational medicine · 26 Aug 2026 PMID 42647597
- Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
- Intratracheal Delivery of mRNA Lipid Nanoparticles Reprograms Alveolar Macrophages for Pulmonary Cancer Immunotherapy. ACS nano · 11 Aug 2026 PMID 42579432
- An LNP-encapsulated mRNA vaccine targeting the major capsid protein of largemouth bass virus confers protective immunity and reduces RIG-I pathway activation in Micropterus salmoides. Fish & shellfish immunology · 30 Jun 2026 PMID 42379032
- Spatiotemporal atlas of pro-inflammatory NF-κB and anti-inflammatory STAT6 signaling using reporter mice during mRNA vaccination. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Jun 2026 PMID 42231579
- Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines. Biochemical and biophysical research communications · 22 May 2026 PMID 42172905
Unclassified: not yet indexed with MeSH (1)
- Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses. Cell reports. Medicine · 3 Aug 2026 PMID 42546698
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-08-31. Last written: 2026-09-09 by GPT. Drafted by language models from published abstracts; not medical advice.